An interventional study of Sigh maneuver added to Lung Protective Ventilation and Lung Protective Ventilation alone in Acute Respiratory Distress Syndrome, Adult, Respiratory Insufficiency Requiring Mechanical Ventilation and Critical Illness, sponsored by Michael Humianto. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Michael Humianto · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Sigh maneuver is a periodic deep breath aimed at reopening collapsed alveoli. This single-center, single-blind randomized controlled trial evaluated whether adding a sigh maneuver to Lung Protective Ventilation (LPV) improves acute gas exchange and reduces the incidence of Acute Respiratory Distress Syndrome (ARDS) compared to LPV alone, in mechanically ventilated adult ICU patients at high risk of ARDS (Lung Injury Prediction Score, LIPS > 4). Fifty-two patients were randomized 1:1, stratified by baseline PF ratio, to receive either LPV with an added sigh maneuver (intermittent higher-pressure breaths via a Dräger Evita V300 ventilator) or LPV alone for 20 minutes, following a 20-minute standardization phase. The primary outcome was change in PaO2/FiO2 ratio; secondary outcomes included changes in PaO2, dynamic compliance, ventilatory ratio, PaCO2, and the incidence of ARDS (Berlin criteria) over one week of observation.
This was a single-center, single-blind, randomized controlled trial conducted in the ICU of Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Indonesia. Adult patients (18-65 years) who were intubated and mechanically ventilated for less than 24 hours, with a Lung Injury Prediction Score (LIPS) > 4 and RASS -5, were enrolled by consecutive sampling after informed consent. Exclusion criteria included pre-existing ARDS by Berlin criteria, chronic pulmonary disease, ventilator PEEP > 8 cmH2O, or refractory hemodynamic instability. After a 20-minute ventilator standardization phase (Phase 0) using a standard LPV protocol (Pressure Control-BiPAP, tidal volume 6 mL/kg predicted body weight, PEEP \<= 8 cmH2O, respiratory rate \<= 20/min, FiO2 titrated to SpO2 > 95%), patients were randomized 1:1 (stratified permuted block randomization by baseline PF ratio category) to a sigh group (LPV plus an added sigh maneuver: intermittent PEEP targeting twice the tidal volume or a peak inspiratory pressure of 30 cmH2O, once per minute, 1-3 seconds per cycle) or a control group (LPV alone) for a further 20 minutes (Phase 1). The outcome assessment team was blinded to group allocation. Arterial blood gas and ventilator parameters were recorded at the end of Phase 0 and Phase 1. Patients were then observed for up to one week (Phase 2) for the development of ARDS according to Berlin criteria. Data were analyzed on an intention-to-treat basis using SPSS version 30.
1,388 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
This study's enrollment of 52 is below the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.
Browse Respiratory Distress Syndrome studies →This is the only study on the registry with Michael Humianto as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Received standard Lung Protective Ventilation (LPV) plus an added sigh maneuver (intermittent higher-pressure breaths, 1 cycle/min, 1-3 seconds/cycle) for 20 minutes, continued through the 1-week observation period.
Procedure: Sigh maneuver added to Lung Protective Ventilation
Received standard Lung Protective Ventilation (LPV) alone, without the sigh maneuver.
Procedure: Lung Protective Ventilation alone
Intermittent higher-pressure ventilator breaths delivered via a Dräger Evita V300 ventilator, targeting twice the tidal volume or a peak inspiratory pressure of 30 cmH2O, at a frequency of 1 cycle/minute, lasting 1-3 seconds per cycle, added on top of standard LPV settings.
Pressure Control-BiPAP ventilation with tidal volume 6 mL/kg predicted body weight, PEEP \<= 8 cmH2O, respiratory rate \<= 20/min, FiO2 titrated to SpO2 \> 95%, without the sigh maneuver feature activated.
Change in PaO2/FiO2 (P/F) ratio
Difference in PaO2/FiO2 ratio (mmHg) between the end of the intervention phase (Phase 1, after 20 minutes of ventilation with or without sigh maneuver) and the end of the standardization phase (Phase 0). PaO2 was obtained from arterial blood gas analysis and divided by the set FiO2. A higher value indicates improved oxygenation.
Time frame: 20 minutes
Change in PaO2
Difference in arterial partial pressure of oxygen (PaO2, mmHg) between the end of Phase 1 and the end of Phase 0, measured by arterial blood gas analysis using a blood analyzer at the hospital clinical pathology laboratory. A higher value indicates improved oxygenation.
Time frame: 20 minutes
Change in dynamic compliance (Cdyn)
Difference in dynamic compliance (mL/mbar) between the end of Phase 1 and the end of Phase 0. Cdyn was read from the Dräger Evita V300 ventilator display as the average of breath-by-breath values over 1 minute. A higher value indicates better lung elasticity.
Time frame: 20 minutes
Change in ventilatory ratio (VR)
Difference in ventilatory ratio between the end of Phase 1 and the end of Phase 0. VR = (measured minute ventilation x measured PaCO2) / (predicted minute ventilation x predicted PaCO2), with predicted values based on predicted body weight (6 mL/kg tidal volume). A value near 1 indicates ventilation matching physiological needs; a value above 1 suggests increased dead space or ventilatory inefficiency. A decrease indicates improved ventilation efficiency.
Time frame: 20 minutes
Change in PaCO2
Difference in arterial partial pressure of carbon dioxide (PaCO2, mmHg) between the end of Phase 1 and the end of Phase 0, measured by arterial blood gas analysis. PaCO2 reflects alveolar ventilation status (normal range 35-45 mmHg).
Time frame: 20 minutes
Incidence of Acute Respiratory Distress Syndrome
Number of participants who developed ARDS during the observation period, assessed as a binary outcome (ARDS vs no ARDS). ARDS was defined by all Berlin criteria: acute onset within 7 days, bilateral opacities on chest X-ray, non-cardiogenic edema, and hypoxemia.
Time frame: Up to 1 week
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2025 to primary completion in Feb 2026, 2 months.
Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 2 months is below that.
Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →